Related Experiment Videos
Chemopreventive agents: protease inhibitors
1Department of Radiation Oncology, University of Pennsylvania School of Medicine, Philadelphia 19104, USA.
Pharmacology & Therapeutics
|August 5, 1998
Summary
Certain protease inhibitors, like Bowman-Birk inhibitor (BBI), can prevent cancer by inhibiting chymotrypsin. These potent agents are effective at low concentrations and can be applied long after carcinogen exposure.
Area of Science:
- Biochemistry
- Molecular Biology
- Cancer Research
Background:
- Protease inhibitors can prevent carcinogenesis across various models.
- Anticarcinogenic protease inhibitors are potent, irreversible, and effective at low concentrations.
- Bowman-Birk inhibitor (BBI) is a potent chymotrypsin inhibitor studied for cancer chemoprevention.
Purpose of the Study:
- To review the characteristics of anticarcinogenic protease inhibitors, focusing on BBI.
- To explore BBI's role as a human cancer chemopreventive agent.
- To hypothesize the role of Bowman-Birk protease inhibitors in plants.
Main Methods:
- Review of existing literature on protease inhibitors and carcinogenesis.
- Analysis of BBI's properties and efficacy in cancer prevention models.
- Comparison of BBI with human alpha1-antichymotrypsin.
Main Results:
- Anticarcinogenic protease inhibitors, particularly BBI, show potent cancer-preventive abilities.
- BBI is effective at low concentrations and can be administered post-carcinogen exposure.
- BBI and alpha1-antichymotrypsin share similarities in inhibiting chymotrypsin and anti-inflammatory properties.
Conclusions:
- BBI is a promising cancer chemopreventive agent that has advanced to human trials.
- The Bowman-Birk family of protease inhibitors may play a significant role in plant defense.
- BBI is anticipated to be crucial in preventing and treating various diseases, including cancer.